Report Overview

The hereditary angioedema market was valued at USD 3.50 Billion in 2023, driven by the rising cases of hereditary angioedema (HAE) across 8 major markets. The market is anticipated to grow at a CAGR of 7.40% during the forecast period of 2024-2032, with the values likely to reach USD 6.65 Billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

  • The market growth is primarily driven by the rising prevalence of the condition.
  • The rising number of regulatory approvals is fueling the market by enabling the launch of advanced therapies and supporting innovation in the market.
  • The efforts by the market players to expand their reach into new regions are bolstering the market by driving competition among key players.

Hereditary Angioedema Market Overview

Hereditary angioedema is a disorder in which the patient experiences recurrent episodes of severe swelling in various body parts such as limbs, face, intestinal tract, and airway. Episodes that affect the intestinal tract may cause severe abdominal pain, nausea, and vomiting. Further, a swollen airway can restrict breathing and lead to life-threatening obstruction of the airway. It is also common for the patient with this condition to develop a non-itchy rash called erythema marginatum during an attack.

Hereditary Angioedema Market Growth Drivers

FDA Approvals Contributing to Increased Treatment Options and Cost Efficiency

The market growth can be attributed to the rising research and development activities by the researchers backed by key market players and governments. The rise in these clinical studies is significantly contributing to the increase in regulatory applications and approvals, leading to market development. For instance, in June 2024, Alembic Pharmaceuticals Ltd announced that they received the final approval from the United States health regulator for their generic Icatibant injection indicated for the treatment of acute attacks of hereditary angioedema in adults. The FDA approval is poised to bring a new and effective treatment option into the market, potentially solidifying the presence of Alembic Pharmaceuticals Ltd in the market while contributing to market growth.

Rising Collaborations to Expand Accessibility for Medications in Underserved Areas

The market players are increasing efforts to expand their market presence by attempting to serve more regions other than their primary hubs. Market expansion plays a crucial role in increasing the availability of the treatment in other regions and bridging the gaps of unmet need for appropriate treatments. For instance, in June 2024, Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced the expansion of the licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen (genetic name) with Ionis Pharmaceuticals, Inc. (Ionis) to widen its development and commercialisation area to the Asia-Pacific region, including Japan. Otsuka has further planned to submit applications for regulatory approval of donidalorsen in Europe and the Asia-Pacific region. The company plans to apply for regulatory approval and exclusively commercialise the product in Asian-Pacific markets. The collaboration between companies is projected to stimulate market growth by delivering donidalorsen to patients across Asia Pacific and Europe to address the unmet medical needs of patients with HAE.

Hereditary Angioedema Market Trends

Hereditary Angioedema Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

Market Breakup by Route of Administration

  • Intravenous
  • Subcutaneous
  • Others

Market Breakup by End User

  • Hospitals
  • Clinics
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Hereditary Angioedema Market Share

Segmentation Based on Drug Class to Witness Substantial Growth

The market report offers insights into several drug classes, namely, C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, Kallikrein inhibitors and others. Out of these, the C1 Esterase inhibitor drug class dominates the market share due to its established efficacy in both acute and prophylactic treatment. It reduces the frequency and severity of HAE attacks by targeting the root cause which is C1 inhibitor deficiency. It is also available in various formulations (plasma-derived and recombinant), C1 esterase inhibitors are backed by several research, and a long track record of safety and effectiveness.

Subcutaneous Administration Leads Segmentation by Route of Administration

The subcutaneous route of administration leads the market share due to its convenience, improved patient compliance, and effectiveness in delivering therapies. Unlike intravenous administration, subcutaneous treatments can often be self-administered at home, reducing healthcare costs and enhancing patient comfort. This has contributed to the rise in preference for this administration method for long-term prophylactic treatments.

Hereditary Angioedema Market Analysis by Region

Based on region, the market is segmented into the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom Japan and India. The regional market is dominated by the United States due to the presence of a well-established healthcare infrastructure and high awareness of the condition. The market dominance can also be attributed to the availability of advanced therapies, strong investment in research and development, and the presence of major pharmaceutical companies, bolstering the region’s leadership. The presence of a large patient pool and favourable reimbursement policies that enable individuals to access expensive treatments, resulting in increased diagnoses, propels market growth.

Leading Players in the Hereditary Angioedema Market

The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Takeda Pharmaceutical Company

Takeda Pharmaceutical is a global leader based in Japan. The company has a significant presence in the HAE market, primarily through its Firazyr, which is commonly used for the treatment of acute HAE attacks in adults. Takeda also offers Takhzyro, a preventive treatment for HAE, enhancing its portfolio in hereditary angioedema management.

CSL Behring

CSL Behring is a global biotechnology leader that provides a range of therapies for rare and serious diseases,...

Pharvaris N.V.

Pharvaris is a clinical-stage biopharmaceutical company focused on bringing oral therapy to patients suffering...

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals specialises in the development and marketing of novel, oral, small-molecule medicines...

Other key players in the market include Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Adverum Biotechnologies Inc., and Novartis AG., among others.

Key Questions Answered in the Hereditary Angioedema Market

  • What was the hereditary angioedema market value in 2023?
  • What is the hereditary angioedema market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on drug class?
  • How does segmentation by route of administration influence market dynamics?
  • Who are the end-users in the market?
  • What are the major factors aiding the hereditary angioedema market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • What are the major hereditary angioedema market trends?
  • Which drug class is expected to dominate the market?
  • Which route of administration will lead the market segment?
  • Which end-user will lead the market?
  • Who are the key players involved in the hereditary angioedema market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Route of Administration
  • End User
  • Region
Breakup by Drug Class
  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others
Breakup by Route of Administration
  • Intravenous
  • Subcutaneous
  • Others
Breakup by End User
  • Hospitals
  • Clinics
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Takeda Pharmaceutical Company
  • CSL Behring
  • Pharvaris N.V.
  • BioCryst Pharmaceutical Inc.
  • Ionis Pharmaceuticals Inc.
  • KalVista Pharmaceuticals Inc.
  • Sanofi S.A.
  • BioMarin Pharmaceutical Inc.
  • Adverum Biotechnologies Inc.
  • Novartis AG

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124